Clinical trials: Aripiprazole, completed
Healthy Male Adults
Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults
To investigate the bioequivalence of aripiprazole between administration of one ASC-01 tablet (aripiprazole 3 mg/sertraline 100 mg combination drug) and concomitant administration of one aripiprazole 3-mg tablet and two…
- Trial name
- NCT03342963
- Testing
- ASC-01, Aripiprazole and sertraline
- Where
- Japan
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Antipsychotics, Cognition
Change in Brain Metabolism and Cognitive Function by Aripiprazole
Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task.
- Conditions
- Antipsychotics, Cognition, Brain Metabolism, Dopamine Receptor Occupancy
- Trial name
- NCT01562808
- Testing
- Aripiprazole
- Where
- South Korea
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy
A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics
The purpose of this study is to compare capillary (the smallest of a body's blood vessels) and venous whole blood and plasma concentrations of 5 antipsychotics after given of a single oral, immediate-release dose to healthy…
- Trial name
- NCT01607762
- Testing
- Aripiprazole, Quetiapine, Olanzapine
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Alzheimer's Disease
Side Effects of Newer Antipsychotics in Older Adults
This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.
- Conditions
- Schizophrenia, Alzheimer's Disease, Dementia
- Trial name
- NCT00245206
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Bipolar Disorder
Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder
The purpose of this study is to test the effectiveness and tolerability/safety of aripiprazole (Abilify) in children with subsyndromal symptoms of bipolar disorder who also have a parent with bipolar disorder and other family…
- Trial name
- NCT00194012
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Cocaine Abuse
Effects of Aripiprazole on Cocaine Craving and Self-Administration
The purpose of this study is to investigate whether aripiprazole will decrease cocaine self-administration, subjective effects and cravings compared to placebo.
- Trial name
- NCT00373880
- Testing
- Aripiprazole + Cocaine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2 (NCT02305823)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
Metabolic Signatures and Biomarkers in Schizophrenia
We plan to use a metabolomics lipid platform to map biochemical signatures in unmedicated schizophrenic patients prior to and 4 weeks post treatment with the antipsychotic drug aripiprazole and compare that to lipid perturbations…
- Trial name
- NCT00466310
- Testing
- Aripiprazole, Risperidone, Healthy volunteers
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Duke University
Diabetes
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.
- Trial name
- NCT00895921
- Testing
- Olanzapine, Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Device Latency
Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
The purpose of this study is to determine the accuracy of IEM detection by the MIND1 System by completing a series of Patch applications and IEM ingestions in the clinic.
- Trial name
- OSMITTER (NCT02404532)
- Testing
- MIND1 System
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Pan European Collaboration on Antipsychotic Naïve Schizophrenia II
The study is a prospective 2 year multimodal follow-up study of initially antipsychotic-naïve first-episode psychotic patients involving a standardized intervention with monotherapy with aripiprazole during the first 6 weeks.
- Trial name
- PECANSII (NCT02339844)
- Testing
- Aripiprazole
- Where
- Denmark
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
HIV Infections
Bioequivalence Study of Atazanavir 300 mg Capsule
The purpose of this clinical research study is to assess the bioequivalence of atazanavir administered as a single 300 mg capsule relative to two atazanavir 150 mg capsules in healthy subjects.
- Trial name
- NCT00393328
- Testing
- Atazanavir + Ritonavir
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)
The investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) D2 receptors, brain structure, brain function, and information processing to each other and to psychopathology.
- Trial name
- PECANS (NCT01154829)
- Testing
- amisulpride, aripiprazole
- Where
- Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Schizophrenia
Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
Introduction: Schizophrenia is a serious mental illness. For majority of patients it is a lifetime condition,characterized by intermittent episodes of hospitalization due to relapse or acute symptom exacerbation.
- Trial name
- NCT01714011
- Testing
- Ziprasidone, Aripiprazole
- Where
- Malaysia
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Psychotic Disorders, Bipolar Disorder
Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI
The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.
- Conditions
- Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X
- Trial name
- CALM (NCT01739127)
- Testing
- Aripiprazole, Risperidone/Quetiapine
- Where
- Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Depression
Aripiprazole as Augmentation for TRD
A sizeable minority of patients suffering from major depression do not have their full set of depressive symptoms relieved by a single medication.
- Trial name
- NCT00174876
- Testing
- Drug Abilify
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Healthy
Aripiprazole and Effexor XR Drug Interaction Study
The purpose of this clinical research study is to learn whether aripiprazole has effect on the steady-state pharmacokinetics of venlafaxine in healthy subjects.
- Trial name
- NCT00362271
- Testing
- Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.